BECTON, DICKINSON AND COMPANY

(BDX)
  Report
Delayed Nyse  -  04:00 2022-08-05 pm EDT
254.23 USD   +0.68%
08/04BECTON DICKINSON & CO Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
08/04SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Thursday
MT
08/04Becton, Dickinson and Company Seeks M&A
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

BD Launches Combination Test for COVID-19, Influenza A/B and Respiratory Syncytial Virus

06/30/2022 | 03:01am EDT

BD MAX™ Molecular Diagnostic Respiratory Viral Panel CE Marked to IVD Directive

FRANKLIN LAKES, N.J., June 30, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that the BD MAX™ Respiratory Viral Panel (RVP), a new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B and Respiratory Syncytial Virus (RSV), has been CE marked to the IVD directive 98/79/EC.

The test uses a single nasal swab or a single nasopharyngeal swab sample to determine if a patient has COVID-19 or the flu or RSV. It helps eliminate the need for multiple tests or doctor visits and can help clinicians to implement the right treatment plan quickly. The co-testing approach also helps to increase testing capacity during the busy flu season and speeds the time to diagnosis.

"SARS-Cov-2, influenza and RSV are a triple threat, as patient symptoms and clinical presentation can be nearly identical," said Nikos Pavlidis, vice president of Molecular Diagnostics at BD. "A combined testing panel is key to enabling clinicians to quickly and efficiently diagnose, differentiate and treat patients to help manage the spread of the infections."

The BD MAX™ System, a molecular diagnostic platform, is already in use at thousands of laboratories worldwide, and each unit is capable of analyzing hundreds of samples over a 24-hour period. The BD MAX™ RVP assay is an RT- PCR assay that detects and differentiates the mRNA of SARS-CoV-2, flu A, flu B and RSV in approximately two hours, with the easy-to-use and automated workflow of the BD MAX™ System.

The BD RVP assay for BD MAX™ System is an important addition to the extensive number of assays available on the system across respiratory, STI, gastrointestinal, women's health and health care associated infections. The broad menu of assays in combination with the open system capabilities on a fully automated sample-to-result molecular platform make the BD MAX™ System a valued platform for infectious disease testing in thousands of labs worldwide.

BD MAX™ RVP is currently available in countries that recognize the CE mark. BD plans to submit for Emergency Use Authorization from the U.S. Food and Drug Administration in the coming weeks.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 75,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

Contacts:




Media:                                                                     

Investors:

Troy Kirkpatrick                                                       

Francesca DeMartino

VP, Public Relations                                               

SVP, Head of Investor Relations

858.617.2361                                                       

201.847.5743  

troy.kirkpatrick@bd.com                                       

francesca.demartino@bd.com  

 

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-launches-combination-test-for-covid-19-influenza-ab-and-respiratory-syncytial-virus-301578512.html

SOURCE BD (Becton, Dickinson and Company)


© PRNewswire 2022
All news about BECTON, DICKINSON AND COMPANY
08/04BECTON DICKINSON & CO Management's Discussion and Analysis of Financial Condition and ..
AQ
08/04SECTOR UPDATE : Health Care Stocks Mixed Pre-Bell Thursday
MT
08/04Becton, Dickinson and Company Seeks M&A
CI
08/04TRANSCRIPT : Becton, Dickinson and Company, Q3 2022 Earnings Call, Aug 04, 2022
CI
08/04Becton Dickinson Raises FY22 Guidance
DJ
08/04Becton, Dickinson Reports Higher Fiscal Q3 Results, Raises Full-Year Outlook
MT
08/04BECTON DICKINSON AND : BD REPORTS THIRD QUARTER FISCAL 2022 FINANCIAL RESULTS - Form 8-K
PU
08/04BECTON DICKINSON : Fiscal Q3 Earnings Snapshot
AQ
08/04GUIDANCE : (BDX) BD (BECTON DICKINSON AND COMPANY) Forecasts Fiscal Year 2022 EPS Range $1..
MT
08/04Earnings Flash (BDX) BD (BECTON DICKINSON AND COMPANY) Reports Q3 Revenue $4.64B
MT
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations